BioMarck Pharmaceuticals closes on $7.5 million in new financing
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
RALEIGH, N.C. – Startup BioMarck Pharmaceuticals has wrapped up an effort to raise $7.5 million in new financing, according to a filing with the Securities and Exchange Commission.
The close comes five months after the drug research firm secured two more U.S. patents. It also was awarded a $990,000 National Institutes of Health grant in February.
One new patent covers its lead compound which targets mucus in respiratory diseases. The second covers anti-inflammatory research.
BioMarck’s work forces on peptides. The patents will cover treatment of pulmonary diseases related to mucus and airway inflammation, the company said. It also is seeking international patent coverage.
The lung treatment drug, which is undergoing clinical trial, is designed to combat mucus. According to BioMarck, there are no drugs that treat pulmonary disease by targeting the excessive mucus secretion.
BioMarck licensed its technology from N.C. State,
In 2007, BioMarck secured $4 million in venture funding and won U.S. patent coverage for other key parts of its technology.
Kenneth Adler, a professor of cell biology at NCSU, made the discoveries that led to the development of BioMarck’s technology.
Featured
E-mail Preferences
The Skinny
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming
- Entrepreneurship remains at heart of Tech Wire mission
- Flashback: Tech Wire launched 10 years ago today